AUTH/3634/4/22 - Complainant v Daiichi Sankyo

Allegations about an Edoxaban leavepiece

  • Received
    15 April 2022
  • Case number
  • Applicable Code year
  • Completed
    03 April 2023
  • No breach Clause(s)
  • Additional sanctions
  • Appeal
    No appeal

Case Summary

This case was in relation to a promotional leavepiece on how to initiate Lixiana (edoxaban).

Whilst the Panel had some concerns about the material, it ruled no breach of the following Clauses of the 2021 Code on the very narrow point that there was no evidence that it had been made available in any format to health professionals on or before the date of the complaint and the complainant had not established that relevant personnel had not been trained or were not conversant with the Code:

No Breach of Clause 6.1

Requirement that information must be accurate, up-to-date and not misleading

No Breach of Clause 6.2

Requirement that claims/information/comparisons must be capable of substantiation

No Breach of Clause 9.1

Requirement that all relevant personnel must be fully conversant with the Code

No Breach of Clause 2

Requirement that activities or material must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

This summary is not intended to be read in isolation.
For full details, please see the full case report below.